SEN34 Antibody

What is TSEN34 and what cellular function does it serve?

TSEN34 (also known as SEN34 or SEN34L) encodes a catalytic subunit of the tRNA splicing endonuclease complex that plays a crucial role in RNA processing. This protein specifically catalyzes the removal of introns from precursor tRNA molecules, which is essential for the maturation of functional tRNAs necessary for protein synthesis . TSEN34 constitutes one of the two catalytic subunits of this complex and is primarily responsible for the 3'-splice site cleavage during tRNA splicing . The tRNA splicing endonuclease complex identifies and cleaves pre-tRNA at both 5' and 3'-splice sites, releasing the intron and producing two tRNA half-molecules bearing 2',3'-cyclic phosphate and 5'-OH termini .

The proper functioning of this protein is critical since tRNA molecules serve as adaptor molecules in translation, carrying amino acids to ribosomes for protein synthesis. Interestingly, there are no conserved sequences at the splice sites themselves, but the position of the intron within tRNA genes is highly conserved, placing the splice sites at invariant distances from the constant structural features of the tRNA body . Beyond tRNA processing, TSEN34 is also associated with pre-mRNA 3'-end processing factors, suggesting broader functions in RNA metabolism .

What types of TSEN34 antibodies are available for research?

Several types of TSEN34 antibodies are available for research applications, varying in their clonality, host species, and target epitopes:

Polyclonal antibodies recognize multiple epitopes on the TSEN34 protein, potentially providing stronger signals due to multiple binding sites, but with potential variation between batches. The polyclonal antibody PA5-65502 targets an immunogen sequence including: "KLEQASGASSS QEAGSSQAAK EDETSDGQAS GEQEEAGPSS SQAGPSNGVA PLPRSALLVQ LATARPRPVK ARPLDWRVQS KDWPH" . In contrast, monoclonal antibodies like OTI6B3 from Abcam recognize specific epitopes, offering higher specificity and consistency between batches . The choice between these antibody types depends on specific experimental requirements, with polyclonals often preferred for detection and monoclonals for applications requiring high specificity.

What are the validated applications for TSEN34 antibodies?

TSEN34 antibodies have been validated for several key research applications, with specific antibodies optimized for particular techniques:

• Western Blotting (WB): Antibodies such as SAB1400692 and ab236423 (OTI6B3) have been validated for detecting denatured TSEN34 protein in cell or tissue lysates . Western blotting allows researchers to assess TSEN34 expression levels and potential post-translational modifications, with the expected molecular weight of approximately 34 kDa.

• Immunofluorescence (IF): Antibodies like HPA048208 and SAB1400692 enable visualization of TSEN34's subcellular localization through fluorescence microscopy . Given TSEN34's role in RNA processing, it typically shows nuclear localization with potential enrichment in specific nuclear subcompartments.

• Immunohistochemistry (IHC): Antibodies such as HPA041111 and ab236423 (OTI6B3) allow detection of TSEN34 in fixed tissue sections . This application is particularly valuable for examining TSEN34 expression patterns in normal and pathological tissues, especially in neurological disorders associated with TSEN34 mutations.

Each application requires specific optimization of parameters including antibody concentration, incubation conditions, and detection methods to achieve reliable results. Researchers should verify that their chosen antibody has been validated for their intended application and experimental system before proceeding.

What critical considerations should researchers address when designing experiments with TSEN34 antibodies?

When designing experiments using TSEN34 antibodies, researchers should carefully consider several factors to ensure reliable and interpretable results:

• Antibody validation: Verify that the selected antibody has been validated for your specific application (WB, IF, IHC) and species. Most commercial TSEN34 antibodies have been primarily validated for human samples . For each application, review validation data including expected band size, localization pattern, and positive control tissues or cell lines.

• Appropriate controls: Include proper positive and negative controls in all experiments. For positive controls, use cell lines or tissues known to express TSEN34 based on transcriptomic data. Negative controls should include secondary antibody-only samples and, ideally, TSEN34 knockout or knockdown samples. For specificity verification, peptide competition assays can demonstrate specific binding.

• Species reactivity: Most commercial TSEN34 antibodies have been validated specifically for human samples . If working with non-human models, verify cross-reactivity or select antibodies targeting conserved regions. Sequence conservation data indicates approximately 75% identity with mouse and 76% with rat orthologs , suggesting potential cross-reactivity in some cases.

• Sample preparation: Different applications require specific sample preparation methods. For Western blotting, ensure complete protein extraction and denaturation. For immunofluorescence, optimize fixation methods (paraformaldehyde vs. methanol) and permeabilization conditions. For immunohistochemistry, standardize fixation, antigen retrieval, and blocking procedures.

• Biological context: Consider that TSEN34 functions as part of a complex, potentially affecting epitope accessibility in certain applications. Additionally, TSEN34 has multiple protein aliases (LENG5, PCH2C, SEN34, SEN34L) , which should be considered when searching literature and databases.

How can researchers validate the specificity of TSEN34 antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For TSEN34 antibodies, several complementary approaches should be employed:

• Genetic validation approaches:

  • CRISPR/Cas9 knockout: Generate TSEN34-null cells and confirm complete loss of signal

  • RNAi knockdown: Use siRNA or shRNA to reduce TSEN34 expression and observe corresponding reduction in signal intensity

  • Overexpression: Transfect cells with TSEN34 expression constructs and confirm increased signal

• Biochemical validation methods:

  • Western blot analysis: Confirm single band of expected molecular weight (~34 kDa)

  • Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

  • Mass spectrometry: Identify proteins in immunoprecipitated samples to confirm TSEN34 enrichment

• Multiple antibody approach:

  • Compare results using antibodies targeting different epitopes of TSEN34

  • Consistent results across different antibodies increase confidence in specificity

  • Discrepant results warrant further investigation to determine which antibody provides specific detection

• Biophysics-informed validation:

  • Recent advances in antibody technology employ computational models to predict specificity profiles

  • These approaches can identify potential cross-reactivity with structurally similar proteins

  • By analyzing "different binding modes, each associated with a particular ligand," researchers can better understand potential cross-reactivity issues

• Localization consistency:

  • Confirm that observed subcellular localization matches known biology (primarily nuclear for TSEN34)

  • Compare localization pattern with published literature and database resources

  • Aberrant localization patterns may indicate non-specific binding

Western Blot Protocol for TSEN34 Detection:

• Sample preparation:

  • Lyse cells in RIPA buffer with protease inhibitors (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS)

  • Sonicate briefly (3 × 10s pulses) to shear DNA

  • Centrifuge at 14,000×g for 15 minutes at 4°C

  • Quantify protein using BCA or Bradford assay

• SDS-PAGE and transfer:

  • Load 30-50 μg protein per lane on 10-12% SDS-PAGE gel

  • Run at 100V until dye front reaches bottom

  • Transfer to PVDF membrane (0.45 μm) at 100V for 1 hour in ice-cold buffer

• Antibody incubation:

  • Block membrane in 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with primary TSEN34 antibody (e.g., SAB1400692 or ab236423 ) at 1:1000 dilution in 5% BSA/TBST overnight at 4°C

  • Wash 3× with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

  • Wash 3× with TBST, 5 minutes each

• Detection:

  • Apply ECL substrate and image using digital system

  • Expected band size: ~34 kDa for TSEN34

Immunofluorescence Protocol for TSEN34:

• Sample preparation:

  • Culture cells on coverslips to 70-80% confluence

  • Fix with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

• Antibody incubation:

  • Block with 5% normal serum (matching secondary antibody host) in PBS for 1 hour

  • Incubate with primary TSEN34 antibody (e.g., HPA048208 ) at 1:200 dilution overnight at 4°C

  • Wash 3× with PBS, 5 minutes each

  • Incubate with fluorophore-conjugated secondary antibody at 1:500 dilution for 1 hour at room temperature

  • Wash 3× with PBS, 5 minutes each

• Counterstaining and mounting:

  • Counterstain nuclei with DAPI (1 μg/mL) for 5 minutes

  • Mount with anti-fade mounting medium

  • Seal coverslip edges with nail polish

• Imaging:

  • Image using confocal or epifluorescence microscope

  • Expected pattern: Nuclear localization with possible nucleolar enrichment

How can TSEN34 antibodies be used to study neurological disorders?

TSEN34 has been implicated in pontocerebellar hypoplasia type 2 (PCH2C), making TSEN34 antibodies valuable tools for investigating this and related neurological disorders . Several sophisticated research approaches can be employed:

• Comparative tissue analyses:

  • Examine TSEN34 expression patterns in control versus patient-derived brain tissues using immunohistochemistry

  • Focus on cerebellum and other brain regions affected in PCH2C

  • Quantify expression differences through immunoblotting and immunofluorescence intensity measurements

  • Compare cellular and subcellular distribution patterns across different neuronal populations

• Patient-derived cell models:

  • Generate iPSCs from patient samples and differentiate into relevant neural cell types

  • Compare TSEN34 localization, expression levels, and complex formation in control versus patient-derived neurons

  • Use live-cell imaging with fluorescently tagged antibody fragments to track TSEN34 dynamics

  • Combine with RNA sequencing to correlate TSEN34 alterations with transcriptome changes

• Functional studies:

  • Perform co-immunoprecipitation using TSEN34 antibodies to assess complex formation in normal versus diseased states

  • Combine with mass spectrometry to identify alterations in interaction partners

  • Use proximity ligation assays to examine TSEN34 interactions with other complex components in situ

  • Evaluate the impact of disease-associated mutations on TSEN34 localization and function

• Developmental analyses:

  • Track TSEN34 expression during neural development using immunohistochemistry in developing brain tissue

  • Correlate with markers of neuronal differentiation and maturation

  • Examine temporal and spatial expression patterns in animal models of development

  • Compare with human developmental tissue samples where available

These approaches can provide critical insights into how TSEN34 mutations lead to specific patterns of neurodegeneration and may identify potential therapeutic targets for intervention in PCH2C and related disorders.

What recent technological advances enhance TSEN34 antibody applications?

Recent advances in antibody technology and related methodologies have significantly enhanced the capabilities for TSEN34 research:

• Computational antibody design:

  • Novel approaches combine "high-throughput sequencing and downstream computational analysis" to enhance antibody specificity

  • These methods allow "identification of different binding modes, each associated with a particular ligand" to improve target recognition

  • For TSEN34 research, this could enable development of antibodies that distinguish between different conformational states or specifically recognize disease-associated variants

  • The computational approach can "disentangle these modes, even when they are associated with chemically very similar ligands"

• Proximity labeling techniques:

  • BioID or APEX2 fusion proteins can be combined with TSEN34 antibodies for proximity proteomics

  • These approaches identify proteins within nanometer-scale distances of TSEN34 in living cells

  • Enable mapping of the TSEN34 interaction network under different cellular conditions

  • Help identify novel components of the tRNA processing machinery

• Super-resolution microscopy:

  • Techniques such as STORM, PALM, or STED microscopy combined with TSEN34 antibodies

  • Resolve TSEN34 localization at nanometer-scale resolution

  • Visualize the spatial organization of tRNA processing complexes within nuclear subcompartments

  • Detect alterations in complex assembly in disease models

• Single-cell approaches:

  • Integration of TSEN34 antibodies in single-cell proteomics workflows

  • Analysis of cell-to-cell variation in TSEN34 expression and localization

  • Correlation with single-cell transcriptomics to link TSEN34 protein levels to RNA processing outcomes

  • Identification of cell subpopulations with distinct TSEN34 expression patterns

• Recombinant antibody engineering:

  • Development of recombinant TSEN34 antibody fragments with improved specificity and reduced background

  • Engineering of bispecific antibodies to simultaneously target TSEN34 and other complex components

  • Creation of intrabodies that can track TSEN34 in living cells

  • Production of conformation-specific antibodies that recognize active versus inactive states

How can researchers troubleshoot common issues in TSEN34 antibody experiments?

When working with TSEN34 antibodies, researchers may encounter several technical challenges. Here are methodological approaches to address common issues:

• No signal or weak signal in Western blot:

  • Verify TSEN34 expression in your sample type using transcriptomic databases

  • Increase protein loading amount (50-80 μg may be needed for low-abundance proteins)

  • Try alternative extraction methods optimized for nuclear proteins

  • Reduce transfer time or voltage to prevent protein run-through

  • Test different membrane types (PVDF vs. nitrocellulose)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal enhancement systems (e.g., biotin-streptavidin amplification)

• Multiple bands or non-specific bands in Western blot:

  • Increase blocking stringency (5% milk for 2 hours or overnight)

  • Optimize antibody dilution through titration experiments

  • Include 0.1% SDS in antibody dilution buffer to reduce non-specific binding

  • Use freshly prepared samples with complete protease inhibitors

  • Consider if bands represent isoforms, post-translational modifications, or degradation products

  • Perform peptide competition assays to identify specific versus non-specific bands

• High background in immunofluorescence:

  • Optimize fixation protocol (duration, temperature, and fixative composition)

  • Increase blocking time and concentration (10% serum for 2 hours)

  • Include 0.1-0.3% Triton X-100 in antibody dilution buffer

  • Test alternative secondary antibodies with minimal cross-reactivity

  • Include 0.1% BSA in all wash buffers

  • Use confocal microscopy to reduce out-of-focus fluorescence

• Inconsistent immunohistochemistry results:

  • Standardize tissue processing (fixation time, embedding conditions)

  • Optimize antigen retrieval methods (citrate buffer pH 6.0 versus EDTA buffer pH 9.0)

  • Test different antibody incubation times and temperatures

  • Use automated staining platforms for consistency

  • Process control and experimental samples in the same batch

  • Consider epitope masking due to over-fixation or incomplete antigen retrieval

• Cross-reactivity concerns:

  • Validate antibody using TSEN34 knockout or knockdown samples

  • Perform peptide competition assays with the specific immunogen

  • Try alternative antibodies targeting different epitopes

  • Increase washing stringency (higher salt concentration, longer washes)

  • Pre-absorb antibody with tissue lysates from non-expressing samples

These troubleshooting strategies should be systematically applied and documented to identify optimal conditions for TSEN34 detection in specific experimental systems.

How is TSEN34 implicated in neurological disorders and what research approaches are most informative?

TSEN34 mutations have been definitively linked to pontocerebellar hypoplasia type 2 (PCH2C), a severe neurodevelopmental disorder characterized by cerebellar hypoplasia, progressive microcephaly, and profound intellectual disability . This connection between a tRNA processing enzyme and a specific neurological disorder presents several important research questions:

• Mechanistic studies:

  • How do TSEN34 mutations affect tRNA splicing efficiency and fidelity?

  • Why does disrupted tRNA processing particularly affect neural tissues?

  • What downstream processes are most sensitive to alterations in tRNA maturation?

• Research approaches to address these questions include:

  • Biochemical assays comparing wild-type and mutant TSEN34 enzymatic activity

  • RNA-seq analysis of tRNA processing in patient-derived cells

  • Proteomic profiling to identify changes in translation products

  • Development of animal models expressing disease-associated TSEN34 mutations

  • Neurodevelopmental studies examining cerebellar formation in model systems

• Therapeutic exploration:

  • Can gene therapy approaches restore normal TSEN34 function?

  • Are there small molecules that could enhance residual TSEN34 activity?

  • Could targeting downstream pathways mitigate disease phenotypes?

• Comparative studies:

  • How do TSEN34-related disorders compare to other RNA processing disorders?

  • Are there shared pathogenic mechanisms across different forms of pontocerebellar hypoplasia?

  • What can we learn from comparing TSEN34 mutations to mutations in other tRNA splicing complex components?

TSEN34 antibodies are essential tools for these research directions, enabling visualization and quantification of the protein in different experimental contexts. They allow researchers to track expression patterns during development, examine subcellular localization in disease states, and assess the impact of mutations on protein stability and complex formation.

What are the most promising future directions for TSEN34 antibody applications?

Several emerging research directions show particular promise for advancing our understanding of TSEN34 biology and its role in disease:

• Spatial transcriptomics and proteomics:

  • Integration of TSEN34 antibody staining with spatial transcriptomics techniques

  • Mapping tRNA processing activity within tissue architecture

  • Correlation of TSEN34 expression with cell type-specific gene expression programs

  • Examination of regional variations in TSEN34 expression in the developing brain

• Structure-function analysis:

  • Development of conformation-specific antibodies that distinguish between different functional states

  • Antibodies targeting specific post-translational modifications to study regulation

  • Epitope-specific antibodies to probe structural changes in disease-associated mutations

  • Nanobodies for structural studies and potential therapeutic applications

• Single-molecule approaches:

  • Single-molecule imaging of TSEN34 dynamics in living cells

  • Analysis of tRNA processing complex assembly and disassembly kinetics

  • Correlation of TSEN34 activity with local RNA concentration and processing

  • Examination of how disease mutations affect molecular dynamics

• Therapeutic development:

  • Antibody-based imaging agents for visualizing TSEN34 expression in vivo

  • Development of antibody-drug conjugates for targeted therapy

  • Intrabodies as potential therapeutic agents to stabilize mutant TSEN34

  • Antibody fragments as delivery vehicles for gene editing components

• Systems biology approaches:

  • Integration of TSEN34 antibody-based proteomics with transcriptomics and metabolomics

  • Network analysis of TSEN34 interactions in health and disease states

  • Computational modeling of tRNA processing dynamics

  • Multi-omic analyses to understand the systemic impact of TSEN34 dysfunction

These future directions will benefit from continued improvement in antibody technologies, including the computational design approaches described in recent literature that enable "the design of antibodies with customized specificity profiles" . Such advances promise to enhance our understanding of TSEN34's role in both normal cellular function and neurological disease states.

How can TSEN34 antibodies be combined with cutting-edge molecular techniques?

TSEN34 antibodies can be integrated with sophisticated molecular techniques to gain deeper insights into tRNA processing mechanisms:

• CLIP-seq (Cross-Linking Immunoprecipitation sequencing):

  • Identifies RNA molecules directly bound to TSEN34 in vivo

  • Requires antibodies effective under cross-linking conditions

  • Maps precise binding sites on target RNAs

  • Can reveal previously unknown RNA substrates beyond canonical tRNAs

• Proximity proteomics:

  • BioID or APEX2 fusion constructs combined with TSEN34 antibodies

  • Maps proteins in close proximity to TSEN34 in living cells

  • Identifies transient interaction partners missed by conventional co-immunoprecipitation

  • Reveals the broader molecular context of TSEN34 function

• Cryo-electron microscopy:

  • Antibody fragments to facilitate structure determination of TSEN34-containing complexes

  • Visualization of conformational changes associated with catalytic activity

  • Structural insights into disease-causing mutations

  • Understanding of complex assembly and substrate recognition

• Mass spectrometry-based techniques:

  • Immunoprecipitation combined with mass spectrometry to identify TSEN34 interaction partners

  • Detection of post-translational modifications that regulate TSEN34 activity

  • Targeted proteomics to quantify TSEN34 complex components

  • Cross-linking mass spectrometry to map protein-protein interaction interfaces

• Genome editing coupled with imaging:

  • CRISPR-mediated tagging of endogenous TSEN34 for live-cell imaging

  • Introduction of disease-associated mutations to study functional consequences

  • Creation of reporter systems to monitor tRNA processing activity

  • Development of cellular models that recapitulate disease phenotypes

• Nanobody-based applications:

  • Development of TSEN34-specific nanobodies for super-resolution imaging

  • Intracellular expression to track TSEN34 in living cells

  • Modulation of TSEN34 activity through targeted binding

  • Single-domain antibodies as crystallization chaperones for structural studies

These integrated approaches leverage the specificity of TSEN34 antibodies while overcoming some limitations of traditional antibody-based methods, providing multidimensional insights into TSEN34 biology.